Mensa J¹, Barberán J², Soriano A¹, Llinares P³, Marco F⁴, Cantón R⁵, Bou G⁶, González Del Castillo J⁷, Maseda E⁸, Azanza JR⁹, Pasquau J¹⁰, García-Vidal C¹, Reguera JM¹¹, Sousa D³, Gómez J¹², Montejo M¹³, Borges M¹⁴, Torres A¹⁵, Alvarez-Lerma F¹⁶, Salavert M¹⁷, Zaragoza R¹⁸, Oliver A¹⁹.

¹Servicio de Enfermedades Infecciosas, Hospital Clinic, Barcelona, Spain ²Servicio de Medicina Enfermedades infecciosas, Hospital Universitario HM Montepríncipe, Universidad San Pablo CEU. Madrid, Spain ³Unidad de Enfermedades Infecciosas, Complejo Hospitalario Universitario A Coruña, Spain. ⁴Servicio de Microbiología, Hospital Clinic, Barcelona, Spain ⁵Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS). Madrid, Spain ⁶Servicio de Microbiología, Complejo Hospitalario Universitario A Coruña, Spain. ⁷Servicio de Urgencias, Hospital Clínico San Carlos, Madrid, Spain ⁸Servicio de Anestesiología, Hospital Universitario La Paz, Madrid, Spain ⁹Servicio de Farmacología, Clínica Universitaria de Navarra, Pamplona, Spain ¹⁰Servicio de Enfermedades Infecciosas, Hospital Universitario Virgen de la Nieves, Granada, Spain ¹¹Servicio de Enfermedades Infecciosas, Hospital Universitario Carlos Haya, Málaga, Spain ¹²Servicio de Enfermedades Infecciosas, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain ¹³Servicio de Enfermedades Infecciosas, Hospital Universitario Cruces, Bilbao, Spain ¹⁴Servicio de Medicina Intensiva, Hospital Son Llátzer, Palma de Mallorca, Spain ¹⁵Departamento de Neumología, Hospital Clinic, Barcelona, Spain ¹⁶Servicio de Medicina Intensiva, Hospital del Mar, Barcelona, Spain ¹⁷Unidad de Enfermedades Infecciosas. Hospital Univeristario la Fe, Valencia, Spain ¹⁸Servicio de Medicina Intensiva, Hospital Universitario Dr. Peset, Valencia, Spain ¹⁹Servicio de Microbiología, Hospital Universitari Son Espases, Instituto de Investigación Sanitaria Illes Balears (idISBa), Palma de Mallorca, Spain.

Pseudomonas aeruginosa is characterized by a notable intrinsic resistance to antibiotics, mainly mediated by the expression of inducible chromosomic β-lactamases and the production of constitutive or inducible efflux pumps. Apart from this intrinsic resistance, P. aeruginosa possess an extraordinary ability to develop resistance to nearly all available antimicrobials through selection of mutations. The progressive increase in resistance rates in P. aeruginosa has led to the emergence of strains which, based on their degree of resistance to common antibiotics, have been defined as multidrug resistant, extended-resistant and panresistant strains. These strains are increasingly disseminated worldwide, progressively complicating the treatment of P. aeruginosa infections. In this scenario, the objective of the present guidelines was to review and update published evidence for the treatment of patients with acute, invasive and severe infections caused by P. aeruginosa. To this end, mechanisms of intrinsic resistance, factors favoring development of resistance during antibiotic exposure, prevalence of resistance in Spain, classical and recently appeared new antibiotics active against P. aeruginosa, pharmacodynamic principles predicting efficacy, clinical experience with monotherapy and combination therapy, and principles for antibiotic treatment were reviewed to elaborate recommendations by the panel of experts for empirical and directed treatment of P. aeruginosa invasive infections.

Revista Española de Quimioterapia 2018;31(1): 78-100.

Link to Pubmed